Activated protein C for severe sepsis: review
Sadaka et al add their two cents and a cohort study to the Xigris efficacy/safety debate. In their retrospective, propensity-matched analysis of 563 patients sourced from the Project IMPACT database, the 108 who received activated protein C had 35% mortality, vs 54% for the 108 who did not (p=0.005). There were unusually low rates of bleeding (2.8% GI bleeding in APC group, no brain hemorrhages), compared to previous trials of APC. Authors reported no competing interests. Critical Care 2011;15:R89.